Panipenem does not alter the pharmacokinetics of the active metabolite of irinotecan SN-38 and inactive metabolite SN-38 glucuronide (SN-38G) in rats

Anticancer Research

Volumn 31, Issue 9, 2011, Pages 2915-2922

  Kato, Ayako ^a,b   Ueyama, Jun ^a,c   Abe, Fumie ^a,d   Hotta, Kazuo ^a   Tsukiyama, Ikuto ^a   Oshima, Taeyuki ^b   Kondo, Fumio ^a   Saito, Hiroko ^a   Hasegawa, Takaaki ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KINJO GAKUIN UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

^d KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Active metabolite of irinotecan; Glucuronidation; Panipenem; Pharmacokinetics; SN 38; SN 38 glucuronide (SN 38G)

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; ESTRADIOL; HYMECROMONE; PANIPENEM PLUS BETAMIPRON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG GLUCURONIDATION; LOADING DRUG DOSE; MALE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT;

ANIMALS; CAMPTOTHECIN; GLUCURONIDES; MALE; RATS; RATS, SPRAGUE-DAWLEY; THIENAMYCINS;

EID: 80051615098     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Haaz MC, Rivory L, Janter S, Ratanasavanh D and Robert J: Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes. Pharmacol Toxicol 80: 91-96, 1997. (Pubitemid 27078232)
2. Ando Y, Saka H, Asai G, Sugiura S, Shimokata K and Kamataki T: UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 9: 845-847, 1998. (Pubitemid 28440442)
3. Sugiyama Y, Kato Y and Chu X: Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother Pharmacol 42(Suppl): S44-S49, 1998.
4. Nakatomi K, Yoshikawa M, Oka M, Ikegami Y, Hayasaka S, Sano K, Shiozawa K, Kawabata S, Soda H, Ishikawa T, Tanabe S and Kohno S: Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun 288: 827-832, 2001. (Pubitemid 33140956)
5. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T and Kamataki T: Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56: 3752-3757, 1996. (Pubitemid 26272025)
6. Kehrer DF, Sparreboom A, Verweij J, de Bruijn P, Nierop CA, van de Schraaf J, Ruijgrok EJ and de Jonge MJ: Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 7: 36-41, 2001.
7. de Jong FA, Kitzen JJ, de Bruijn P, Verweij L and Loos WJ: Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain. Cancer Biol Ther 5: 1105-1110, 2006. (Pubitemid 44772222)
8. Xie R, Mathijssen RH, Sparreboom A, Verweij J and Karlsson MO: Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther 72: 265-275, 2002.
9. Takasuna K, Hagiwara T, Hirohashi M, Nomura M, Nagai E, Yokoi T and Kamataki T: Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol 42: 280-286, 1998. (Pubitemid 28393844)
10. Gupta E, Safa AR, Wang X and Ratain MJ: Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res 56: 1309-1314, 1996. (Pubitemid 26080974)
11. Horikawa M, Kato Y and Sugiyama Y: Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. Pharm Res 19: 1345-1353, 2002.
12. Hu Z, Yang X, Ho PC, Chan E, Chan SY, Xu C, Li X, Zhu YZ, Duan W, Chen X, Huang M, Yang H and Zhou S: St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats. Pharm Res 22: 902-914, 2005.
13. Yokoo K, Hamada A, Watanabe H, Matsuzaki T, Imai T, Fujimoto H, Masa K, Imai T and Saito H: Involvement of up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10- hydroxycamptothecin (SN-38) by coadministration of S-1 in rats. Drug Metab Dispos 35: 1511-1517, 2007. (Pubitemid 47296043)
14. Yamamura N, Imura K, Naganuma H and Nishimura K: Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats. Drug Metab Dispos 27: 724-730, 1999. (Pubitemid 29252448)
15. Narayanan R, LeDuc B and Williams DA: Determination of the kinetics of rat UDP-glucuronosyltransferases (UGTs) in liver and intestine using HPLC. J Pharm Biomed Anal 22: 527-540, 2000. (Pubitemid 30151242)
16. Hanioka N, Takeda Y, Tanaka-Kagawa T, Hayashi K, Jinno H and Narimatsu S: Interaction of bisphenol A with human UDP-glucuronosyltransferase 1A6 enzyme. Environ Toxicol 23: 407-412, 2008.
17. Lucier GW, McDaniel OS, Bend JR and Faeder E: Effects of hycanthone and two of its chlorinated analogs on hepatic microsomes. J Pharmacol Exp Ther 186: 416-424, 1973.
18. Hanioka N, Jinno H, Nishimura T, Ando M, Ozawa S and Sawada J: High-performance liquid chromatographic assay for glucuronidation activity of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in human liver microsomes. Biomed Chromatogr 15: 328-333, 2001. (Pubitemid 32816153)
19. Hanioka N, Jinno H, Tanaka-Kagawa T, Nishimura T and Ando M: Determination of UDP-glucuronosyltransferase UGT1A6 activity in human and rat liver microsomes by HPLC with UV detection. J Pharm Biomed Anal 25: 65-75, 2001. (Pubitemid 32234400)
20. Shiratani H, Katoh M, Nakajima M and Yokoi T: Species differences in UDP-glucuronosyltransferase activities in mice and rats. Drug Metab Dispos 36: 1745-1752, 2008.
21. Canal P, Gay C, Dezeuze A, Douillard JY, Bugat R, Brunet R, Adenis A, Herait P, Lokiec F and Mathieu-Boue A: Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 14: 2688-2695, 2006.
22. Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, Vernillet L, Risse ML, Boige V, Gouyette A and Vassal G: Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 6: 2012-2020, 2000. (Pubitemid 30305100)
23. Humerickhouse R, Lohrbach K, Li L, Bosron WF and Dolan ME: Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 60: 1189-1192, 2000. (Pubitemid 30151980)
24. de Jong FA, de Jonge MJ, Verweij J and Mathijssen RH: Role of pharmacogenetics in irinotecan therapy. Cancer Lett 234: 90-106, 2006.
25. Kawato Y, Aonuma M, Hirota Y, Kuga H and Sato K: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187-4191, 1991.
26. Atsumi R, Suzuki W and Hakusui H: Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 21: 1159-1169, 1991.
27. Rivory LP and Robert J: Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 36: 176-179, 1995.
28. Kaneda N and Yokokura T: Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 50: 1721-1725, 1990.
29. Lepine J, Bernard O, Plante M, Tetu B, Pelletier G, Labrie F, Belanger A and Guillemette C: Specificity and regioselectivity of the conjugation of estradiol, estrone and their catecholestrogen and methoxyestrogen metabolites by human uridine diphosphoglucuronosyltransferases expressed in endometrium. J. Clin Endocrinol Metab 89: 5222-5232, 2004. (Pubitemid 39391472)
30. Lokiec F, Canal P, Gay C, Chatelut E, Armand JP, Roché H, Bugat R, Gonçalvès E and Mathieu-Boué A: Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother Pharmacol 36: 79-82, 1995.
31. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL and Ratain MJ: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101: 847-854, 1998. (Pubitemid 28096082)
32. Tallman MN, Ritter JK and Smith PC: differential rates of glucuronidation for 7-ethyl-10-hydroxycamptothecin (SN-38) lactone and carboxylate in human and rat microsomes and recombinant UDP-glucuronosyltransferase isoforms. Drug Metab Dispos 33: 977-983, 2005. (Pubitemid 41002780)
33. Tallman MN, Miles KK, Kessler FK, Nielsen JN, Tian X, Ritter JK and Smith PC: The contribution of intestinal UDP-glucuronosyltransferases in modulating 7-ethyl-10-hydroxycamptothecin (SN-38)-induced gastrointestinal toxicity in rats. J Pharmacol Exp Ther 320: 29-37, 2007. (Pubitemid 46025716)
34. Gagné JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C: Common human UGTlA polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62: 608-617, 2002. (Pubitemid 36329379)
35. Tajima N, Soma M, Ishizuka H and Naganuma H: Quantitative evaluation of effect of renal failure on the pharmacokinetics of panipenem in rats. Biol Pharm Bull 28: 2170-2172, 2005. (Pubitemid 41634276)
36. Shibayama T, Matsushita Y, Kawai K, Hirota T, Ikeda T and Kuwahara S: Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals. Antimicrob Agents Chemother 51: 257-263, 2007. (Pubitemid 46047715)
37. Suzuki E, Yamamura N, Ogura Y, Nakai D, Kubota K, Kobayashi N, Miura S and Okazaki O: Identification of valproic acid glucuronide hydrolase as a key enzyme for the interaction of valproic acid with carbapenem antibiotics. Drug Metab Dispos 38: 1538-1544, 2010.
38. Kessler FK, Kessler MR, Auyeung DJ and Ritter JK: Glucuronidation of acetaminophen catalyzed by multiple rat phenol UDP-glucuronosyl transferases. Drug Metab Dispos 30: 324-330, 2002. (Pubitemid 34175025)